Completed PHASE3 INTERVENTIONAL 1-arm NCT00221468

A Study of Quetiapine for the Treatment of Mood Disorders in Adolescents

A Single-Blind Prospective Study of Quetiapine for the Treatment of Mood Disorders in Adolescents

Sponsor: AstraZeneca

Interventions quetiapine

Updated 5 times since 2017 Last updated: Jul 17, 2012 Started: Jun 30, 2003 Primary completion: Apr 30, 2006 Completion: Apr 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00221468, this PHASE3 trial focuses on Mood Disorders and remains completed. Sponsored by AstraZeneca, it has been updated 5 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
University of Cincinnati

Data source: University of Cincinnati

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cincinnati, United States